BTYNB

Description: BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 µM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates beta-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-kappaB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association. Target: c-Myc, Others, NF-kappaB. Smiles: NC(=O)c1ccccc1\N=C\c1ccc(Br)s1. References: Mahapatra L , Andruska N , Mao C , et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation[J]. Translational Oncology, 2017, 10(5):818-827.